Ascletis Pharma surged 23.3% in Hong Kong.

Ascletis Pharma announced that its 13-week Phase II study (NCT07002905) evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity has achieved positive top-line results. In addition to delivering statistically significant and clinically meaningful weight loss, ASC30 also met its secondary and exploratory endpoints. Across all dose groups, ASC30 reduced multiple established cardiovascular risk markers, including total cholesterol, LDL-C, triglycerides, as well as systolic and diastolic blood pressure. At steady state, ASC30 exposure increased with dose.